Form 4/A for INSP Inspire Medical Systems, Inc.
Accepted 2023-03-13 00:00:00 ET · period of report 2022-03-17 · accession 0001104659-23-031814 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MA | 2023-03-13 | 2022-03-17 | INSP | Herbert Timothy P. | CEO, Pres, Dir | S - Sale | $225.35 | -18.8K | 114.8K | -14% | -$4.23M |
| MAI | 2023-03-13 | 2022-03-17 | INSP | Herbert Timothy P. | CEO, Pres, Dir | S - Sale | $226.17 | -1,229 | 118.7K | -1% | -$278.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-17 | S | D | 18,731 | $225.35 | 114,790 | D By trust | — | — | (F1) This Form 4 amends and restates the previously reported sale transactions made by the Reporting Person that occurred on March 17, 2022 in order to reallocate such sales between the Reporting Person and a trust that is considered beneficially owned by the Reporting Person. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.00 to $225.995. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F3) The amount of securities listed in Column 5 reflects the total shares held following the transaction owned by the Reporting Person, by reference to the total reported in the Reporting Person's Form 4 filed on March 13, 2023. The total has increased from such Form 4 as a result of the prior overstatement of the sale of shares directly held by the Reporting Person on March 17, 2022 by 1,229 shares, which is corrected herein. (F6) Securities held by the Timothy P. Herbert 2018 Family Continuation Trust c/u the Timothy P. Herbert 2018 Grantor Retained Annuity Trust. |
| 2 | Common | Common Stock | 2022-03-17 | S | D | 40 | $226.04 | 114,790 | D By trust | — | — | (F3) The amount of securities listed in Column 5 reflects the total shares held following the transaction owned by the Reporting Person, by reference to the total reported in the Reporting Person's Form 4 filed on March 13, 2023. The total has increased from such Form 4 as a result of the prior overstatement of the sale of shares directly held by the Reporting Person on March 17, 2022 by 1,229 shares, which is corrected herein. (F6) Securities held by the Timothy P. Herbert 2018 Family Continuation Trust c/u the Timothy P. Herbert 2018 Grantor Retained Annuity Trust. |
| 3 | Common | Common Stock | 2022-03-17 | S | D | 1,193 | $226.13 | 118,778 | I | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.04 to $226.65. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F5) The amount of securities listed in Column 5 reflects the total shares held following the transaction based on the total reported in the Reporting Person's most recent Form 4, dated March 13, 2023. |
| 4 | Common | Common Stock | 2022-03-17 | S | D | 36 | $227.53 | 118,742 | I | — | — | (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.515 to $227.58. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |